Company intelligence / Profile preview

PCRopsis

Miami, Florida, United Statespcropsis.com ↗

Ownership: Private
Development stage: Commercial

Overview

PCRopsis develops innovative reagents and devices that enable direct nucleic acid extraction from diverse biological samples using engineered nanoparticles. Their products simplify workflows by eliminating traditional multi-step RNA/DNA purification processes—enabling direct-to-PCR protocols that are compatible with automation. The company’s Oral Rinse device allows easy at-home oral sample collection with room temperature stability of RNA up to seven days. Their technologies have been applied in infectious disease diagnostics—including COVID‑19—and oncology research.

Therapeutic areas: OtherOncologyInfectious Diseases
Modalities: DeviceNanoparticle-based reagentDiagnostic reagent
Industry: Molecular Diagnostics

Partnerships

Strategic academic and industry collaborations mentioned but not specified by name.

Beyond the preview

Go deeper on PCRopsis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCRopsis.

Explore the full profile